Antibody Immunoassay for HBV Pre-S2 Deletion Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pre-S2 deletion mutant large hepatitis B virus surface protein are labor-intensive and inaccurate, making it difficult to assess the risk of hepatocellular carcinoma (HCC) in chronic HBV carriers and HCC patients post-hepatectomy surgery.
Innovation Solution
Development of a specific antibody-based immunoassay kit that uses recombinant proteins and peptides to detect pre-S2 deletion mutant LHBS, allowing for the calculation of its levels in biological samples without interference from wild-type LHBS, thereby assessing HCC risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA hybridization techniques are used to detect pre-S2 deletion mutant LHBS, then detection capability is achieved, but the process becomes labor-intensive and complex
Solution Approach 1:
The patent replaces complex mechanical/DNA-based detection systems with an immunoassay system using antibodies. Specifically, it uses an antibody specific to the pre-S2 region that distinguishes between wild-type and mutant LHBS through immunological reactions rather than DNA hybridization, thereby simplifying the detection process while maintaining accuracy
Solution Approach 2:
The patent extracts and detects only the specific pre-S2 deleted mutant protein from the complex mixture of HBV surface proteins. By using antibodies that specifically recognize the deleted pre-S2 region, the method isolates and detects only the relevant mutant form without interference from other proteins, reducing analytical complexity
2Measurement precision
If specific antibodies are developed to detect pre-S2 deletion mutant LHBS, then detection accuracy is improved, but development time and complexity increase
Solution Approach 1:
The patent performs preliminary action by pre-coating the assay plate with capture antibodies specific to the pre-S2 region before sample addition. This pre-prepared setup allows for rapid detection without requiring complex real-time differentiation steps during the actual detection process, thereby reducing assay time while maintaining high accuracy
Solution Approach 2:
The patent segments the detection process into distinct steps: capture of total LHBS by pre-coated antibodies, followed by detection of wild-type versus mutant forms using different antibodies. This segmentation allows parallel processing and simplifies the overall workflow, reducing total assay time while maintaining detection accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoassay kit provides a rapid and accurate method for detecting pre-S2 deletion mutant LHBS, reducing the complexity of previous DNA hybridization techniques and improving the assessment of HCC risk in HBV carriers and post-surgical HCC patients.
Implementation Method 1
a large hepatitis B virus surface protein (LHBS)-specific antibody, specifically binding to a recombinant protein
Implementation Method 2
an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant large hepatitis B virus surface protein
Data Source
AI summary
A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.